Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
17%(1 trials)

Phase Distribution

Ph phase_3
1
17%
Ph phase_1
1
17%
Ph phase_2
4
67%

Phase Distribution

1

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
4(66.7%)
Phase 3Large-scale testing
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(6)

Detailed Status

Completed6

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (16.7%)
Phase 24 (66.7%)
Phase 31 (16.7%)

Trials by Status

completed6100%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_2

Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer

NCT03081481
completedphase_2

Transperineal Intraprostatic Injection of PRX302 Under Ultrasound Guidance for Management of Prostatic Hyperplasia

NCT00889707
completedphase_3

Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of Intraprostatic PRX302 for LUTS BPH

NCT01966614
completedphase_2

Evaluate, Safety and Tolerability of Intraprostatic PRX302 Administration, Low to Intermediate Risk Prostate Cancer

NCT02499848
completedphase_1

Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH)

NCT01454349
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT03081481Phase 2

Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer

Completed
NCT00889707Phase 2

Transperineal Intraprostatic Injection of PRX302 Under Ultrasound Guidance for Management of Prostatic Hyperplasia

Completed
NCT01966614Phase 3

Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of Intraprostatic PRX302 for LUTS BPH

Completed
NCT02499848Phase 2

Evaluate, Safety and Tolerability of Intraprostatic PRX302 Administration, Low to Intermediate Risk Prostate Cancer

Completed
NCT01454349Phase 1

Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH)

Completed
NCT00686088Phase 2

An Open-Label, Multi-Center, Phase IIa Trial of PRX302 Treatment of Patients With Locally Recurrent Prostate Cancer After Primary Radiation Therapy

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6